GlobalData on MSN5 天
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...
MPR10 小时
Wearable Furosemide Delivery System Approved for CKD Patients
The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...
The Pharma Letter5 天
FDA nod for scPharmaceuticals’ Furoscix sNDA
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...
Pharmaceutical Technology5 天
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients including those with nephrotic syndrome. Credit: Orawan Pattarawimonchai ...
scPharmaceuticals announces FDA approval of Furoscix indication expansion
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...
Nasdaq5 天
ScPharma: FDA Approves FUROSCIX For Treating Edema In Chronic Kidney Disease Patients
(SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication to include treatment of edema in ...